Trader 📈 bio-hacker 🧬 and weight lifter 💪🏼 Disclosure: Opinions only, not investment advice. DYOR. High risk, High reward stocks.
🇺🇸
Joined November 2024
- Tweets1.4K
- Following279
- Followers148
- Likes7.1K
David retweeted
$LEXX has 3 agreements with pharma companies right now.
1. Original MTA holder. Exclusive, twice extended. Speculated to be $NVO / $LLY
2. PegBio. Would open up huge Chinese oral GLP1 market.
3. Pharma Company agreement announced yesterday. $LLY / $MDGL / $ABBV $VKTX or some other.
These are only the announced agreements. Easily could be multiple NDA’s behind the scenes 👀
Recent PR “accelerating business development”
“Renewed interest in other forms of API”
$LEXX has 3 agreements with pharma companies right now.
1. Original MTA holder. Exclusive, twice extended. Speculated to be $NVO / $LLY
2. PegBio. Would open up huge Chinese oral GLP1 market.
3. Pharma Company agreement announced yesterday. $LLY / $MDGL / $ABBV $VKTX or some other.
These are only the announced agreements. Easily could be multiple NDA’s behind the scenes 👀
Recent PR “accelerating business development”
“Renewed interest in other forms of API”
David retweeted
$LEXX has 3 agreements with pharma companies right now.
1. Original MTA holder. Exclusive, twice extended. Speculated to be $NVO / $LLY
2. PegBio. Would open up huge Chinese oral GLP1 market.
3. Pharma Company agreement announced yesterday. $LLY / $MDGL / $ABBV $VKTX or some other.
These are only the announced agreements. Easily could be multiple NDA’s behind the scenes 👀
Recent PR “accelerating business development”
“Renewed interest in other forms of API”
$LEXX has 3 agreements with pharma companies right now.
1. Original MTA holder. Exclusive, twice extended. Speculated to be $NVO / $LLY
2. PegBio. Would open up huge Chinese oral GLP1 market.
3. Pharma Company agreement announced yesterday. $LLY / $MDGL / $ABBV $VKTX or some other.
These are only the announced agreements. Easily could be multiple NDA’s behind the scenes 👀
Recent PR “accelerating business development”
“Renewed interest in other forms of API”
David retweeted
$LEXX cash on hand alone prices stock at $4.60. 70 patents. Current agreements with 3 pharmaceutical companies. 1 is a global pharma company, one is PegBio which could open the HUGE Chinese market and the third is an unknown pharma co announced today. Human results pending.
Also let’s not forget that several months ago Lexaria said directly in their press release that there was renewed interest in other forms of API. Hypertension, CBD and nicotine.
Open your eyes and do your research! 🧐 👀 📈
$LEXX cash on hand alone prices stock at $4.60. 70 patents. Current agreements with 3 pharmaceutical companies. 1 is a global pharma company, one is PegBio which could open the HUGE Chinese market and the third is an unknown pharma co announced today. Human results pending.
Also let’s not forget that several months ago Lexaria said directly in their press release that there was renewed interest in other forms of API. Hypertension, CBD and nicotine.
Open your eyes and do your research! 🧐 👀 📈
David retweeted
$LEXX 3rd pharmaceutical agreement 🔥.
$LEXX Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH accessnewswire.com/newsroom/…
$LEXX 3rd pharmaceutical agreement 🔥.
$LEXX Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH accessnewswire.com/newsroom/…
David retweeted
Another MTA signed - that's now 3 in total
$LEXX
lexariabioscience.com/2026/1…
David retweeted
$LEXX human study results due and currently signed in an exclusive MTA with a global pharma partner 👀 $NVO / $LLY
Morgan Stanley Forecasts the GLP-1 Market Could Reach $190 Billion by 2035, but That May Be Too Conservative
A new Motley Fool article argues that the biggest growth opportunities for GLP-1 treatments from $NVO and $LLY may still lie ahead.
According to Morgan Stanley, the global obesity treatment market could reach $190 billion by 2035, more than double its estimated size in 2025.
Several developments could support this growth:
• Oral treatments: Obesity pills could attract patients who prefer tablets over injections.
• International expansion: More than one billion people with obesity live outside the United States, with markets such as China and Brazil offering substantial opportunities.
• Expanded medical indications: Certain GLP-1 treatments have demonstrated benefits in cardiovascular disease, kidney disease, liver disease, and sleep apnea.
However, the article highlights another particularly interesting development.
Could GLP-1 treatments slow biological aging?
A recent NIH-funded study found that healthy older mice treated with semaglutide, the active ingredient in Ozempic and Wegovy, demonstrated improvements in muscle and cognitive function.
Researchers also observed reductions in several biological markers associated with aging, including inflammation.
Interestingly, some of these benefits appeared to extend beyond the effects of reduced calorie intake.
However, these findings come from animal research and do not establish that semaglutide slows aging in humans.
The Motley Fool contributor believes that if future research demonstrates similar benefits in humans, the GLP-1 market could become substantially larger than current forecasts suggest.
The article also highlights $PFE as another pharmaceutical company developing treatments targeting this growing market.
For investors, the opportunity may extend far beyond obesity and diabetes.
However, a rapidly expanding market does not guarantee equally strong earnings growth for every manufacturer. Competition, pricing pressure, and clinical trial outcomes will determine which companies benefit most.
Link: fool.com/investing/2026/11/0…
$LEXX human study results due and currently signed in an exclusive MTA with a global pharma partner 👀 $NVO / $LLY
Morgan Stanley Forecasts the GLP-1 Market Could Reach $190 Billion by 2035, but That May Be Too Conservative
A new Motley Fool article argues that the biggest growth opportunities for GLP-1 treatments from $NVO and $LLY may still lie ahead.
According to Morgan Stanley, the global obesity treatment market could reach $190 billion by 2035, more than double its estimated size in 2025.
Several developments could support this growth:
• Oral treatments: Obesity pills could attract patients who prefer tablets over injections.
• International expansion: More than one billion people with obesity live outside the United States, with markets such as China and Brazil offering substantial opportunities.
• Expanded medical indications: Certain GLP-1 treatments have demonstrated benefits in cardiovascular disease, kidney disease, liver disease, and sleep apnea.
However, the article highlights another particularly interesting development.
Could GLP-1 treatments slow biological aging?
A recent NIH-funded study found that healthy older mice treated with semaglutide, the active ingredient in Ozempic and Wegovy, demonstrated improvements in muscle and cognitive function.
Researchers also observed reductions in several biological markers associated with aging, including inflammation.
Interestingly, some of these benefits appeared to extend beyond the effects of reduced calorie intake.
However, these findings come from animal research and do not establish that semaglutide slows aging in humans.
The Motley Fool contributor believes that if future research demonstrates similar benefits in humans, the GLP-1 market could become substantially larger than current forecasts suggest.
The article also highlights $PFE as another pharmaceutical company developing treatments targeting this growing market.
For investors, the opportunity may extend far beyond obesity and diabetes.
However, a rapidly expanding market does not guarantee equally strong earnings growth for every manufacturer. Competition, pricing pressure, and clinical trial outcomes will determine which companies benefit most.
Link: fool.com/investing/2026/11/0…